TP53 and non-small cell lung carcinoma: We found that a TP53 and ATM comutation was associated with better OS than a TP53 mutation alone, an ATM mutation alone, and no mutation among patients with any cancer (NSCLC median OS: TP53 and ATM comutation, not reached; TP53 mutation alone, 11.0 months; ATM mutation alone, 16.0 months; no mutation 14.0 months, P = .24; any cancer median OS: TP53 and ATM comutation; TP53 mutation alone, 14.0 months; ATM mutation alone, 40.0 months; no mutation, 22.0 months; P < .001) (Figure 3; eFigure 5, eTable 4, and eTable 5 in the Supplement).